In cardiac surgery patients, the composite primary endpoint occurred in 170 (24%) patients given exenatide and 165 (24%) in the other group, and exenatide did not significantly reduce it.
In plain wordsIn cardiac surgery patients, the composite primary outcome occurred in 24% of exenatide recipients and 24% of the other group, with no significant reduction.
- Peptide
- Exenatide (exendin-4)
- Outcome
- No significant changeComposite death, stroke, dialysis-requiring renal failure or new/worsening heart failure
- Study
n = 1,389
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- 17.4 µg · infusion · during cardiopulmonary bypass and first hour after weaningAs given in this study (human).
Measurements
- Primary endpoint events
- 170 patients
- exenatide
- Primary endpoint incidence
- 24%
- exenatide
- Primary endpoint events
- 165 patients
- comparison group
- Primary endpoint incidence
- 24%
- comparison group
Source sentences
Within a follow-up period of a median of 5.9 years (min-max; 2.5-8.3 years), 170 (24%) patients in the exenatide group and 165 (24%) patients experienced a primary end point.
3 context sentences(design, population, supporting numbers)
The main outcome was time to a composite end point consisting of death, stroke, renal failure requiring dialysis, or new/worsening heart failure during follow-up.
We included adult patients undergoing elective cardiopulmonary bypass-assisted coronary artery bypass grafting or aortic valve replacement.
The intervention was an infusion of 17.4 µg of exenatide or placebo during cardiopulmonary bypass and the first hour after weaning thereof.